Progress of Stem Cell Therapy in Interventional Regenerative Medicine
Guan Siwen1, Liu Xuan2, Liu Gang1,2*
1(Guangxi Engineering Center in Biomedical Materials for Tissue and Organ Regeneration, Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning 530021, China) 2(Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, Fujian, China)
Abstract：Interventional regenerative medicine (IRM) is a cross-discipline that achieves repair and regeneration of damaged organs through image-guided minimally invasive surgery and locoregional delivery of stem cells. In recent years, stem cell-based regenerative therapy has shown great promise in the preclinical setting, however, most intravenously delivered cells become trapped in the lungs and reticuloendothelial system, resulting in little cell reaching target tissues, so that the clinical results have been still suboptimal. IRM aims to increase the efficacy of stem cell-based regenerative therapies by locoregional targeted delivery of stem cell via endovascular, endoluminal, or direct injection into tissues and organs. In this review, we summarized the stem cell sources in regenerative therapies, the disease classifications, routes of delivery and mechanisms of action involved in the targeted delivery of stem cells. We showed the development of stem cell therapy in IRM. The application prospects and the barriers to translation of IRM were also discussed.
[1] Hoogduijn MJ, Lombardo E. Mesenchymal Stromal Cells Anno 2019: dawn of the therapeutic era? Concise review[J]. Stem Cells Transl Med,2019,8(11):1126-1134. [2] Zhao Lu, Chen Shanquan, Shi Xiaowei, et al. A pooled analysis of mesenchymal stem cell-based therapy for liver disease[J]. Stem Cell Res Ther,2018,9(1):72. [3] Jang MJ, You D, Park JY, et al. Hypoxic preconditioned mesenchymal stromal cell therapy in a rat model of renal ischemia-reperfusion injury: development of optimal protocol to potentiate therapeutic efficacy[J]. Int J Stem Cells,2018,11(2):157-167. [4] Kanelidis AJ, Premer C, Lopez J, et al. Route of delivery modulates the efficacy of mesenchymal stem cell therapy for myocardial infarction: A meta-analysis of preclinical studies and clinical trials [J]. Circ Res,2017,120(7):1139-1150. [5] Eggenhofer E, Luk F, Dahlke MH, et al. The life and fate of mesenchymal stem cells[J]. Front Immunol,2014,5:148. [6] Tsuchiya A, Kojima Y, Ikarashi S, et al. Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases [J]. Inflamm Regen,2017,37:16. [7] Cho HM, Lee KH, Shen Yiming, et al. Transplantation of hMSCs genome edited with LEF1 improves cardio-protective effects in myocardial infarction[J]. Mol Ther Nucleic Acids, 2020,19: 1186-1197. [8] Zhang Dongsheng, Fan Guochang, Zhou Xiaoyang, et al. Over-expressing of CXCR4 of mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium[J]. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy[J]. J Mol Cell Cardiol, 2008, 44(2):281-292. [9] Vrtovec B, Poglajen G, Lezaic L, et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy [J]. Circulation,2013,128(11 Suppl 1):S42-S49. [10] Silva LH, Cruz FF, Morales MM, et al. Magnetic targeting as a strategy to enhance therapeutic effects of mesenchymal stromal cells [J]. Stem Cell Res Ther,2017,8(1):58. [11] Van der Spoel TI, Vrijsen KR, Koudstaal S, et al. Transendocardial cell injection is not superior to intracoronary infusion in a porcine model of ischaemic cardiomyopathy: a study on delivery efficiency [J]. J Cell Mol Med,2012,16(11):2768-2776. [12] Cunningham CJ, Redondo-Castro E, Allan SM. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke [J]. J Cereb Blood Flow Metab,2018,38(8):1276-1292. [13] Boncoraglio GB, Ranieri M, Bersano A, et al. Stem cell transplantation for ischemic stroke[J]. Cochrane Database Syst Rev,2019,5(5):D7231. [14] Yang Bing, Migliati E, Parsha K, et al. Intra-arterial delivery is not superior to intravenous delivery of autologous bone marrow mononuclear cells in acute ischemic stroke [J]. Stroke,2013,44(12):3463-3472. [15] Vasconcelos-Dos-Santos A, Rosado-De-Castro PH, Lopes DSS, et al. Intravenous and intra-arterial administration of bone marrow mononuclear cells after focal cerebral ischemia: is there a difference in biodistribution and efficacy? [J]. Stem Cell Res,2012,9(1):1-8. [16] Zhang Honglian, Xie Xufang, Xiong Yingqiong, et al. Comparisons of the therapeutic effects of three different routes of bone marrow mesenchymal stem cell transplantation in cerebral ischemic rats [J]. Brain Res,2018,1680:143-154. [17] Li G, Bonamici N, Dey M, et al. Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies [J]. Expert Opin Drug Deliv,2018,15(2):163-172. [18] Cui Yuanbo, Ma Shanshan, Zhang Chunyan, et al. Human umbilical cord mesenchymal stem cells transplantation improves cognitive function in Alzheimer's disease mice by decreasing oxidative stress and promoting hippocampal neurogenesis[J]. Behav Brain Res,2017,320:291-301. [19] Kim JY, Kim DH, Kim JH, et al. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques [J]. Cell Death Differ,2012,19(4):680-691. [20] Santamaria G, Brandi E, Vitola P, et al. Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer's mice [J]. Cell Death Differ,2021,28(1):203-218. [21] Pan Yijun, Nicolazzo JA. Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics[J]. Adv Drug Deliv Rev,2018,135:62-74. [22] Sun Yaoxiang, Shi Hui, Yin Siqi, et al. Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes mellitus by reversing peripheral insulin resistance and relieving β-cell destruction [J]. ACS Nano,2018,12(8):7613-7628. [23] Bhansali S, Dutta P, Kumar V, et al. Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: a randomized, placebo-controlled comparative study [J]. Stem Cells Dev,2017,26(7):471-481. [24] Pawitan JA, Yang Zheng, Wu Yingnan, et al. Towards standardized stem cell therapy in type 2 diabetes mellitus: a systematic review [J]. Curr Stem Cell Res Ther,2018,13(6):476-488. [25] Sood V, Mittal BR, Bhansali A, et al. Biodistribution of 18F-FDG-labeled autologous bone marrow-derived stem cells in patients with type 2 diabetes mellitus: exploring targeted and intravenous routes of delivery [J]. Clin Nucl Med,2015,40(9):697-700. [26] Sood V, Bhansali A, Mittal BR, et al. Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus-defining adequate administration methods[J]. World J Diabetes,2017,8(7):381-389. [27] Lee KC, Lin Hanchieh, Huang Yihsiang, et al. Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease [J]. J Hepatol,2015,63(6):1405-1412. [28] Milosavljevic N, Gazdic M, Simovic MB, et al. Mesenchymal stem cells attenuate acute liver injury by altering ratio between interleukin 17 producing and regulatory natural killer T cells [J]. Liver Transpl,2017,23(8):1040-1050. [29] Gholamrezanezhad A, Mirpour S, Bagheri M, et al. In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis [J]. Nucl Med Biol,2011,38(7):961-967. [30] Andreone P, Catani L, Margini C, et al. Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical tria l[J]. Dig Liver Dis,2015,47(12):1059-1066. [31] Sang Jianfeng, Shi Xiaolei, Han Bin, et al. Intraportal mesenchymal stem cell transplantation prevents acute liver failure through promoting cell proliferation and inhibiting apoptosis[J]. Hepatobiliary Pancreat Dis Int,2016,15(6):602-611. [32] Rigato M, Monami M, Fadini GP. Autologous cell therapy for peripheral arterial disease: systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies [J]. Circ Res,2017,120(8):1326-1340. [33] Xie Baocheng, Luo Houlong, Zhang Yusheng, et al. Autologous stem cell therapy in critical limb ischemia: a meta-analysis of randomized controlled trials [J]. Stem Cells Int,2018,2018:7528464. [34] Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy [J]. J Vasc Surg,2011,53(2):445-453. [35] Raval Z, Losordo DW. Cell therapy of peripheral arterial disease: from experimental findings to clinical trials[J]. Circ Res,2013,112(9):1288-1302. [36] Klepanec A, Mistrik M, Altaner C, et al. No difference in intra-arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemi a[J]. Cell Transplant, 2012,21(9):1909-1918. [37] Matsui F, Babitz SK, Rhee A, et al. Mesenchymal stem cells protect against obstruction-induced renal fibrosis by decreasing STAT3 activation and STAT3-dependent MMP-9 production [J]. Am J Physiol Renal Physiol, 2017,312(1):F25-F32. [38] Zhuo W, Liao L, Fu Y, et al. Efficiency of endovenous versus arterial administration of mesenchymal stem cells for ischemia-reperfusion- induced renal dysfunction in rats [J]. Transplant Proc,2013,45(2):503-510. [39] Tögel FE, Westenfelder C. Kidney protection and regeneration following acute injury: progress through stem cell therapy [J]. Am J Kidney Dis,2012,60(6):1012-1022. [40] Swaminathan M, Stafford-Smith M, Chertow GM, et al. Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery[J]. J Am Soc Nephrol,2018,29(1):260-267. [41] Perico N, Casiraghi F, Remuzzi G. Mesenchymal stromal cells for AKI after cardiac surgery[J]. J Am Soc Nephrol, 2018, 29(1):7-9.
